Clinical Trials Browser

Phase 1/2 × Unknown × pembrolizumab × Clear all

NCT03789097 2024-01-30

Vaccination With Flt3L, Radiation, and Poly-ICLC

Phase 1/2 Unknown

BreastHead & NeckLymphoid

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Lymphoma, Lymphoma, Non-Hodgkin

NCT02557321 2023-11-21

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

Phase 1/2 Unknown

Melanoma

NCT04546074 2023-10-03

Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma

Phase 1/2 Unknown

Melanoma

NCT05708950 2023-07-13

A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

Phase 1/2 Unknown

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Breast Neoplasms, Carcinoma, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms

NCT05127590 2023-07-03

RBN-2397 in Combination With Pembrolizumab in Patients With SCCL

Phase 1/2 Unknown

Advanced Squamous Non-Small Cell Lung Carcinoma

NCT05175235 2023-03-03

Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements

Phase 1/2 Unknown

Neoplasms

NCT05541445 2022-09-15

Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC

Phase 1/2 Unknown

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04262427 2022-08-23

CAPER

Phase 1/2 Unknown

Carcinoma, Renal Cell

NCT05053880 2021-11-19

A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme

Phase 1/2 Unknown

Glioblastoma, Neoplasms

NCT02305186 2021-08-13

UVA-PC-PD101

Phase 1/2 Unknown

Gastrointestinal

Pancreatic Neoplasms

NCT02901301 2021-04-06

Pembrolizumab, Trastuzumab, HER2 Positive Gastric Cancer

Phase 1/2 Unknown

Gastrointestinal

Stomach Neoplasms

NCT04699643 2021-01-07

FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors

Phase 1/2 Unknown

Other solid neoplasm

Advanced Solid Tumors

NCT03525782 2018-05-16

Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02758587 2018-03-19

Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)

Phase 1/2 Unknown

GastrointestinalOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Pancreatic Neoplasms

NCT03446911 2018-02-27

Combining SBRT and Immunotherapy in Early Stage NSCLC Patients Planned for Surgery

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT02990416 2016-12-13

A-dmDT390-bisFv(UCHT1) Fusion Protein With Ionizing Radiation and Pembrolizumab for the Treatment of Stage IV Melanoma

Phase 1/2 Unknown

Melanoma

NCT02430363 2016-02-24

Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475

Phase 1/2 Unknown

Glioblastoma, Gliosarcoma